These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34168057)

  • 1. SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry.
    Arrambide G; Llaneza-González MÁ; Costa-Frossard França L; Meca-Lallana V; Díaz EF; Moreno-Torres I; García-Domínguez JM; Ortega-Suero G; Ayuso-Peralta L; Gómez-Moreno M; Sotoca-Fernández JJ; Caminero-Rodríguez AB; Rodríguez de Antonio LA; Corujo-Suárez M; Otano-Martínez MA; Pérez-Miralles FC; Reyes-Garrido V; Ayuso-Blanco T; Balseiro-Gómez JJ; Muñoz-Pasadas M; Pérez-Molina I; Arnal-García C; Domingo-Santos Á; Guijarro-Castro C; Íñiguez-Martínez C; Téllez Lara N; Castellanos-Pinedo F; Castillo-Triviño T; Cerdán-Santacruz DM; Pérez-Sempere Á; Torres BS; Álvarez de Arcaya A; Costa-Arpín E; Durán-Ferreras E; Fragoso-Martínez M; González-Platas M; Landete Pascual L; Millán-Pascual J; Oreja-Guevara C; Meca-Lallana JE
    Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(5):. PubMed ID: 34168057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
    Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
    Safavi F; Nourbakhsh B; Azimi AR
    Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
    Simpson-Yap S; De Brouwer E; Kalincik T; Rijke N; Hillert JA; Walton C; Edan G; Moreau Y; Spelman T; Geys L; Parciak T; Gautrais C; Lazovski N; Pirmani A; Ardeshirdavanai A; Forsberg L; Glaser A; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton R; Salter A; Fox RJ; van der Walt A; Butzkueven H; Alroughani R; Ozakbas S; Rojas JI; van der Mei I; Nag N; Ivanov R; Sciascia do Olival G; Dias AE; Magyari M; Brum D; Mendes MF; Alonso RN; Nicholas RS; Bauer J; Chertcoff AS; Zabalza A; Arrambide G; Fidao A; Comi G; Peeters L
    Neurology; 2021 Nov; 97(19):e1870-e1885. PubMed ID: 34610987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis.
    Salter A; Fox RJ; Newsome SD; Halper J; Li DKB; Kanellis P; Costello K; Bebo B; Rammohan K; Cutter GR; Cross AH
    JAMA Neurol; 2021 Jun; 78(6):699-708. PubMed ID: 33739362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
    Sormani MP; De Rossi N; Schiavetti I; Carmisciano L; Cordioli C; Moiola L; Radaelli M; Immovilli P; Capobianco M; Trojano M; Zaratin P; Tedeschi G; Comi G; Battaglia MA; Patti F; Salvetti M;
    Ann Neurol; 2021 Apr; 89(4):780-789. PubMed ID: 33480077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
    Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-modifying therapies, outcomes, risk factors and severity of COVID-19 in multiple sclerosis: A MENACTRIMS registry based study.
    Zeineddine M; Al-Hajje A; Salameh P; Massouh J; Saab G; Al-Roughani R; Ahmed SF; Al-Mahdawi A; Shalaby N; Inshasi J; Sahraian MA; Gouider R; Mrabet S; Al-Khabouri J; Shayganneja V; Chentouf A; Boumediene F; Yamout B
    Mult Scler Relat Disord; 2024 Oct; 90():105790. PubMed ID: 39121598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity.
    Simpson-Yap S; Pirmani A; Kalincik T; De Brouwer E; Geys L; Parciak T; Helme A; Rijke N; Hillert JA; Moreau Y; Edan G; Sharmin S; Spelman T; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton RM; Salter A; Bebo B; Van der Walt A; Butzkueven H; Ozakbas S; Boz C; Karabudak R; Alroughani R; Rojas JI; van der Mei IA; Sciascia do Olival G; Magyari M; Alonso RN; Nicholas RS; Chertcoff AS; de Torres AZ; Arrambide G; Nag N; Descamps A; Costers L; Dobson R; Miller A; Rodrigues P; Prčkovska V; Comi G; Peeters LM
    Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36038263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.
    Louapre C; Maillart E; Roux T; Pourcher V; Bussone G; Lubetzki C; Papeix C
    Rev Neurol (Paris); 2020 Jun; 176(6):523-525. PubMed ID: 32362357
    [No Abstract]   [Full Text] [Related]  

  • 12. Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?
    Lonergan R; Kinsella K; Duggan M; Jordan S; Hutchinson M; Tubridy N
    Mult Scler; 2009 Dec; 15(12):1528-31. PubMed ID: 19995848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 in ocrelizumab-treated people with multiple sclerosis.
    Hughes R; Whitley L; Fitovski K; Schneble HM; Muros E; Sauter A; Craveiro L; Dillon P; Bonati U; Jessop N; Pedotti R; Koendgen H
    Mult Scler Relat Disord; 2021 Apr; 49():102725. PubMed ID: 33482590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 in multiple sclerosis patients and risk factors for severe infection.
    Chaudhry F; Bulka H; Rathnam AS; Said OM; Lin J; Lorigan H; Bernitsas E; Rube J; Korzeniewski SJ; Memon AB; Levy PD; Schultz L; Javed A; Lisak R; Cerghet M
    J Neurol Sci; 2020 Nov; 418():117147. PubMed ID: 32980780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
    Holmén C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T
    Mult Scler; 2011 Jun; 17(6):708-19. PubMed ID: 21228027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple sclerosis in Pakistan.
    Wasay M; Ali S; Khatri IA; Hassan A; Asif M; Zakiullah N; Ahmed A; Malik A; Khealani B; Haq A; Fredrikson S
    Mult Scler; 2007 Jun; 13(5):668-9. PubMed ID: 17548448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 in MS: Initial observations from the Pacific Northwest.
    Bowen JD; Brink J; Brown TR; Lucassen EB; Smoot K; Wundes A; Repovic P
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32457226
    [No Abstract]   [Full Text] [Related]  

  • 18. COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series.
    Luetic G; Menichini ML; Burgos M; Alonso R; Carnero Contentti E; Carrá A; Deri N; Steinberg J; Rojas JI;
    Mult Scler Relat Disord; 2021 Aug; 53():103049. PubMed ID: 34130197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple sclerosis clinical course and cardiovascular disease risk - Swedish cohort study.
    Roshanisefat H; Bahmanyar S; Hillert J; Olsson T; Montgomery S
    Eur J Neurol; 2014 Nov; 21(11):1353-e88. PubMed ID: 25041631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.